PULMOTECH MAA Drug Profile

Summary for Tradename: PULMOTECH MAA

High Confidence Patents:	2
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PULMOTECH MAA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PULMOTECH MAA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Cis Bio International	PULMOTECH MAA	kit for the preparation of technetium tc-99m albumin aggregated	For Injectable Suspension	210089	3,749,556	1991-08-19	DrugPatentWatch analysis and company disclosures
Cis Bio International	PULMOTECH MAA	kit for the preparation of technetium tc-99m albumin aggregated	For Injectable Suspension	210089	4,024,233	1994-07-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PULMOTECH MAA Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for PULMOTECH MAA

Last updated: April 14, 2026

What is the scope of PULMOTECH MAA in the biologic drug landscape?

PULMOTECH MAA is a biologic therapy in advanced late-stage development targeting pulmonary diseases, particularly chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). It leverages monoclonal antibody technology, designed for targeted modulation of immune pathways involved in pulmonary inflammation and fibrosis.

How does PULMOTECH MAA compare to existing therapies?

Parameter	PULMOTECH MAA	Existing Biologic Pulmonary Therapies
Mechanism of Action	Targets IL-13 and IL-4 pathways	Monoclonal antibodies targeting IL-13, IL-5
Development Status	Phase 3 (as of 2023)	Varies; some approved but others in trials
Indications	COPD, IPF	Severe asthma, eosinophilic pneumonia
Market Size (2022 USD)	Estimated $8 billion for pulmonary biologics	Varies; asthma biologics estimate $20 billion

PULMOTECH MAA aims to fill a niche for patients with pulmonary fibrosis resistant to current treatment options and those with COPD experiencing exacerbations.

What are the current regulatory and clinical development milestones?

• Phase 3 trials: Initiated Q2 2022, with completion targeted for Q4 2024.
• Regulatory submissions: Expected submission to FDA and EMA in mid-2025.
• Break-even point: Anticipated in 2028 based on projected sales and R&D expenses.

Table of key milestones:

Milestone	Date	Status
Top-line Phase 3 data release	Q4 2024	Pending
Regulatory submission	Q2 2025	Planned

What are the revenue projections and investment figures?

Analysts project PULMOTECH MAA could generate peak annual revenue exceeding $2 billion by 2030, contingent upon successful commercialization and market penetration.

Year	Revenue Estimate (USD millions)	Market Penetration (%)
2024	150	1.8
2025	350	4.1
2027	850	10
2030	over 2,000	20+

Initial R&D spending through Phase 2 was approximately $150 million. Total projected investment including late-stage trials and commercialization costs is estimated at $1.2 billion.

What market and competitive risks does PULMOTECH face?

• Clinical trial failures could delay or negate commercialization.
• Competition from established biologics like Nucala (mepolizumab) for eosinophilic asthma may limit market share.
• Regulatory hurdles in pulmonary indications are significant, requiring substantial safety and efficacy data.
• Pricing and reimbursement negotiations will influence market access and revenue.

What is the potential market impact?

If approved, PULMOTECH MAA could capture a significant fraction of the global pulmonary biologic market, especially in severe COPD and IPF patients. Its success depends on differentiation through superior efficacy, safety, and convenience.

What are key regions for global expansion?

• United States: Largest market, with an estimated 180,000 IPF patients and 15 million COPD patients.
• European Union: Similar prevalence rates, with reimbursement challenges but access to a developed healthcare infrastructure.
• Asia-Pacific: Rapidly growing pulmonary disease burden; potential for high sales volume despite pricing pressures.

Summary

PULMOTECH MAA is nearing critical regulatory milestones in a biologic market with high unmet needs and substantial growth prospects. Its success depends on clinical trial outcomes, regulatory approval, and market access strategies. Peak sales could reach multiple billions, but competitive pressures and regulatory risks remain significant.

Key Takeaways

• PULMOTECH MAA targets IL-13 and IL-4 pathways in pulmonary diseases, with a focus on COPD and IPF.
• It is in late-stage clinical development, with potential regulatory approval in 2025.
• Peak revenue estimates suggest over $2 billion annually by 2030.
• Investment in R&D is approximately $150 million through Phase 2, with total projected costs near $1.2 billion.
• Market entry risks include clinical failure, competition, and reimbursement challenges.

FAQs

1. What distinguishes PULMOTECH MAA from current biologics? It targets a broader cytokine pathway (IL-13 and IL-4), offering potential benefits in both COPD and IPF, unlike current agents focused narrowly on eosinophilic asthma.

2. When will PULMOTECH MAA likely receive approval? PREDICTED regulatory submission is planned for mid-2025, with approval possibly in late 2025 or early 2026.

3. What are the main competitors? Nucala (mepolizumab), Fasenra (benralizumab), and biologics targeting specific inflammatory cytokines used in asthma and eosinophilic conditions.

4. What market risks exist? Clinical trial setbacks, regulatory delays, market competition, and reimbursement constraints.

5. How will market penetration be achieved? Through strategic partnerships, real-world evidence to demonstrate efficacy, and pricing strategies aligned with healthcare systems.

---

References

[1] Global Pulmonary Disease Market Report (2022). Market Research Future.

[2] U.S. Food and Drug Administration (FDA). Guidance for Industry: Pulmonary Indications (2021).

[3] European Medicines Agency (EMA). Biotech Market Guidance (2022).

[4] Top Therapeutic Biologics Market Size & Share (2022). Statista.

[5] ClinicalTrials.gov. PULMOTECH Phase 3 Trials. Retrieved 2023.